Capital doesn't fix a GTM problem. It exposes one.
European fundraising has gotten structurally harder to access on the old timeline, not just harder to close at 2021-era valuations. Atomico's State of European Tech 2025 projects $44bn raised across the region this year, essentially flat against $43bn in 2023 and $41bn in 2024. But the more telling number sits underneath the headline: the median time between venture rounds in Europe reached 696 days in Q2 2025, up 5% year over year, and 46% of European seed financings in Q1 2025 were bridges rather than new priced rounds. The practical read is that investors are asking companies to prove more GTM efficiency before committing new capital, not less.
This connects directly to the two metrics covered elsewhere in the Operator System's GTM Insights. Bessemer's guidance draws the line cleanly: before a company has both product-market fit and a scalable sales and marketing motion, it should raise and spend as little as possible; once both exist, it should raise and deploy as much as the organisation can absorb to compound growth. The problem most founders run into is that "scalable motion" is exactly what stalls in the €1M–€3M ARR band Notion Capital and Kyle Poyar call the stumbling block zone, and a CAC payback stuck at the 18-month industry median is a direct signal to an investor that the motion isn't scalable yet. Funding readiness is a downstream consequence of GTM readiness. It is not a separate track that can be worked in parallel.
The down-round data confirms this from the other direction. Down rounds sit at 14.9% of all European rounds in 2025, concentrated in companies that raised on growth-at-any-cost narratives in 2020 and 2021 and could not show the unit economics to justify the mark on a second look. Capital was available to those companies once. It is not automatically available twice. The founders who raise cleanly on a second round are, almost without exception, the ones who can produce a working GTM motion, not the ones with the better growth story.
The funding spectrum, and what each instrument actually costs
Bootstrapping is a financing decision, not the absence of one. SaaS Capital's 2026 Annual Benchmarking Survey of bootstrapped companies at €3M–€20M ARR reports median revenue growth of 15%, Net Revenue Retention of 103%, and Gross Revenue Retention of 91%. That is meaningfully slower than the growth rates venture investors underwrite, but it comes with full ownership and no repayment obligation. The trade is speed for control: a bootstrapped company compounds more slowly but never has to justify its GTM decisions to a board.
Venture equity remains the default path for companies aiming at the outcome Christoph Janz's SaaS Funding Napkin describes: a business that can plausibly reach €100M ARR while still growing fast when it gets there. It is expensive in ownership terms. Carta's data on software financing rounds shows median dilution of roughly 19–20% at seed and 18% at Series A, down from 20.9% a year earlier, which leaves a typical founding team with around 56% of the company after seed and 36% after Series A. Each round compounds the last: the same data shows a hypothetical company retaining just over 40% of its equity by Series D, an improvement on the roughly one-third that dilution schedules left five years earlier, but still a majority of the company gone.
Venture debt is not a substitute for equity. It is a complement to it. Structured as a term loan sized at 20–35% of the most recent equity round, typically priced at a floating rate (commonly quoted as SOFR plus 6–9%) with a 3–6% end-of-term fee and warrants covering 0.5–2% of equity, it extends runway without repricing the company. The European Investment Bank's own EUR 25M venture debt facility signals that government-backed lending is now supplementing commercial venture debt providers in the region. The precondition that matters: it works as an extension to a round that already happened, not as a replacement for one that didn't.
Revenue-based financing, offered in Europe by providers including Wayflyer, Uncapped, Outfund, and Berlin's re:cap, prices capital against monthly recurring revenue rather than equity or covenants. Cost runs roughly 1.2 to 1.5 times the capital advanced under the commonly cited industry norm, though structures vary and some providers use a flat fee instead of a multiple. It is non-dilutive and fast to close, but it requires predictable, high-margin recurring revenue to underwrite, which rules it out pre-product-market-fit and makes it a tool for extending a working motion, not for building one.
What investors are actually underwriting
Net Revenue Retention is the single number most investors weight above headline growth. SaaS Capital's benchmarking data segments this by contract value: companies with average contracts above €100,000 report top-quartile NRR of 118–120%, while companies in the €25,000–€50,000 range see a median of 102%, with the top quartile at 111%. Below 100% at any segment signals that the existing customer base is shrinking net of expansion, which no amount of new-logo growth reliably offsets.
Gross retention is the guardrail underneath NRR. SaaS Capital's data puts best-in-class gross retention at around 95% for mid-market and enterprise-focused companies; below 85% points to a product-market fit or onboarding problem that new revenue cannot outrun. Bessemer's Rule of 40, growth rate plus profit margin, is the summary metric boards use to compare efficiency across companies growing at different rates, and Bessemer's own research finds that companies consistently clearing the Rule of 40 threshold command roughly double the revenue multiple of less efficient peers.
The core precondition, per Christoph Janz, is that venture capital only makes sense for a company that actually wants to build toward €100M ARR while still growing quickly at that size, not for a company that would be better served by reaching profitability faster on its own terms. Most SaaS companies, in his assessment, are not VC-compatible businesses. That is not a criticism. It is a statement about what the instrument is priced to reward.
When each option earns its cost, and when it doesn't
Bootstrapping is right when the ACV and gross margin support profitable growth without external GTM investment, and wrong when the market opportunity is truly time-limited, since compounding slowly against a category a competitor is capturing with venture speed is its own form of risk.
Venture equity is right once product-market fit and a scalable, documented GTM motion both exist, which is exactly Bessemer's dividing line, and wrong before that point, since capital raised against a growth story rather than a repeatable motion tends to fund the stumbling-block-zone failure pattern rather than solve it. The reward is velocity and a partner with capital for the next round. The cost is permanent, compounding dilution and a board that expects the growth rate the capital was priced on.
Venture debt is right as an extension to a round that already closed, commonly cited as buying 6–9 months of additional runway without a new valuation event, and wrong as a way to avoid raising equity a company actually needs, since covenants and repayment obligations bite hardest exactly when growth disappoints, which is also when equity would have been hardest to raise anyway.
Revenue-based financing is right for extending a proven, high-margin recurring revenue motion between rounds, or for avoiding a new equity event entirely, and wrong pre-product-market-fit or on thin gross margins, since the effective cost, sometimes obscured behind a flat fee rather than a stated rate, compounds fastest against exactly the companies least able to absorb it. The useful discipline before signing any revenue-based financing agreement: ask the provider for the implied annual rate under a base-case and a slow-growth scenario, and validate it independently.